Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | MIF | P14174 | 7/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.78 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | MAOB | P27338 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825321 | 1.00 | CYP19A1 (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL4221371 | 0.88 | CYP19A1 (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL4221374 | 0.88 | CYP19A1 (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL4221377 | 0.88 | CYP19A1 (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL4229532 | 0.87 | CYP19A1 (0.97) | CYP19A1MIFPKMALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL4229528 | 0.87 | CYP19A1 (0.97) | CYP19A1MIFPKMALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL4230487 | 0.87 | CYP19A1 (0.97) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL30852868 | 0.85 | MAPT (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL30852828 | 0.85 | MAPT (1.00) | CYP19A1MIFPKMALDH1A1KMT2A | |
| SCHEMBL13851846 | 0.84 | CYP19A1 (1.00) | CYP19A1MIFPKMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028110-B1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1023063-B1 | INDENO[1,2-c], NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6559157-B2 | Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-06 | — | — | US | disclosed |
| US-6451834-B1 | Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1028110-A1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | Yukijirushi Nyugyo Kabushiki Kaisha (JP) | 2000-08-16 | — | — | EP | disclosed |
| EP-0557075-B1 | 4H-naphtho 1,2-b pyran derivatives as antiproliferative agents | LILLY CO ELI (GB) | 1998-06-24 | — | — | EP | disclosed |
| EP-0618206-B1 | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5663375-A | CELL PROLIFERATION | ELI LILLY AND COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5622987-A | PREVENT MIGRATION OR PROLIFERATION OF SMOOTH MUSCLE CELLS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5576325-A | TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5574034-A | TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5571818-A | FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR | ELI LILLY AND COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| US-5378699-A | Treatment of immune diseases, cell proliferation, restenosis and smooth muscle cells | LILLY INDUSTRIES LIMITED (GB) | 1995-01-03 | — | — | US | disclosed |
| US-5378717-A | Therapy for diabetic complications | ELI LILLY AND COMPANY (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0618206-A1 | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1994-10-05 | — | — | EP | disclosed |
| EP-0557075-A1 | 4H-naphtho 1,2-b pyran derivatives as antiproliferative agents | LILLY INDUSTRIES LIMITED (GB) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | CYP19A1, HSD17B11, CYP17A1 | CYP19A1 1/4885MIF 606/4885PKM 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.